Table 2. Correlations between the expression of PD-Ls or tumor-infiltrating CD8+ lyphocytes and clinicopathological characteristics in ovarian carcinosarcoma (n = 19).

Variable	Intraepithelial PD-L1 expression				Mesenchymal PD-L1 expression			Intraepithelial CD8+ TIL			Mesenchymal CD8 + TIL
	n	Negative	Positive	P	Negative	Positive	P	Negative	Positive	P	Negative	Positive	P
Age				0.605			0.650			1.000			0.338
<58	8	4	4		5	3		4	4		1	7
≥58	11	6	5		5	6		6	5		4	7
Stage				0.800			0.528			0.528			1.000
I	2	1	1		2	0		0	2		0	2
II	5	2	3		3	2		3	2		1	4
III	12	7	5		5	7		7	5		4	8
Histology subtype				0.996			0.998			0.656			1.000
Homologous	9	5	4		5	4		4	5		2	7
Heterologous	10	5	5		5	5		6	4		3	7
Menopause status				0.087			0.906			0.303			1.000
Premenopausal	4	4	0		2	2		1	3		1	3
Postmenopausal	15	6	9		8	7		9	6		4	11
Pretreatment CA125				0.588			1.000			1.000			1.000
≤ 200 U/ml	4	3	1		2	2		2	2		1	3
> 200 U/ml	14	7	7		7	7		8	6		4	10
Ascitic fluid				0.020			0.650			1.000			0.603
Negative	12	9	3		7	5		6	6		4	8
Positive	7	1	6		3	4		4	3		1	6
Tumor site				0.303			0.141			1.000			0.084
Unilateral	14	6	8		9	5		7	7		2	12
Bilateral	5	4	1		1	4		3	2		3	2
Tumor volume				0.370			0.650			1.000			0.338
≤ 12 cm	11	7	4		5	6		6	5		4	7
> 12cm	8	3	5		5	3		4	4		1	7
Residual tumor				0.350			0.650			0.350			1.000
R0	12	5	7		7	5		5	7		3	9
Visible residual disease	7	5	2		3	4		5	2		2	5
Chemotherapy				0.608			0.608			1.000			1.000
PTX+CBP	10	4	6		4	6		5	5		3	7
IFO/DOX	5	3	2		3	2		3	2		2	3

R0 = no visible disease after cytoreductive surgery. PTX = Paclitaxel; CBP = Carboplatin; IFO = Ifosfamide; DOX = Doxorubicin